Urolithin A Side Effects & Safety

Safety Profile

Potential Side Effects

• Gastrointestinal distress, including nausea or abdominal discomfort, primarily reported in small-scale human trials during acute administration.
• Potential for hypoglycemia in diabetic populations; while human RCTs are limited, the metabolic modulation of mitophagy-related pathways necessitates caution regarding glucose homeostasis.
• Lack of long-term safety data; current human clinical evidence is restricted to short-duration studies (typically 4–12 weeks), leaving long-term effects on systemic mitophagy levels uncharacterized.
• Potential for unknown interactions with drugs targeting mitochondrial biogenesis or metabolic rate, due to the lack of comprehensive pharmacokinetic studies in humans.

Drug & Supplement Interactions

• Potential synergistic effects with mitophagy-inducing agents: Because Urolithin A functions via the activation of PINK1/Parkin-mediated mitophagy, concurrent use with other autophagy-modulating compounds (such as spermidine) lacks sufficient human RCT data to determine if additive effects occur or if cellular signaling pathways reach a saturation point.
• Pharmacokinetic considerations with CYP450 substrates: While human data is limited, Urolithin A is a metabolite produced by gut microbiota from ellagitannins; there is a theoretical risk that high-dose supplementation could influence the metabolic clearance of drugs processed via the cytochrome P450 system, though specific inhibitory or inductive potencies remain uncharacterized in clinical trials.
• Interaction with anti-inflammatory or immunosuppressant drugs: Given Urolithin A's role in modulating inflammatory signaling pathways (such as NF-κB inhibition), there is a theoretical risk of interference with the efficacy of pharmaceutical-grade immunosuppressants or corticosteroids, though no specific clinical studies have quantified this interaction.

Maximum Dose